Mersana Therapeutics logo
Mersana Therapeutics
MRSN | NASDAQ
Chart Builder DCF Calculator
$29.08
$0.00 (0.00%)
At close: Jan 5, 2026, 3:55 PM ET

Mersana Therapeutics Company Profile

Company profile explained

Company Profile

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.

Key Executives

Name Position
Martin H. Huber President, Chief Executive Officer & Director
Alejandra Veronica Carvajal Senior Vice President, Secretary & Chief Legal Officer
Brian C. DeSchuytner Senior Vice President, Chief Financial Officer & Chief Operating Officer
Ashish Mandelia Vice President & Chief Accounting Officer
Chuck Miller Senior Vice President of Regulatory Affairs
Jason Fredette Senior Vice President of Investor Relations & Corporate Communications
Marc Damelin Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
Mikhail Papisov Co-Founder
Mohan Bala Senior Vice President & Chief Development Officer
Timothy Lowinger Senior Vice President and Chief Science & Technology Officer

Latest SEC Filings

Date Type Title
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Feb 17, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Feb 17, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jan 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jan 16, 2026 15-12G Filing
Jan 09, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jan 08, 2026 EFFECT Filing
Jan 08, 2026 SC 13D/A [Amend] Filing
Jan 06, 2026 4 Filing
Jan 06, 2026 4 Filing
View All SEC Filings ➞
Mersana Therapeutics
Mersana Therapeutics logo
Country United States
IPO Date Jun 28, 2017
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Martin H. Huber

Contact Details

840 Memorial Drive Cambridge, Massachusetts 02139 United States

Stock Details

Ticker Symbol MRSN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001442836
CUSIP Number 59045L205
ISIN Number US59045L2051
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.